Faculty profile

Robert Olson

Back to faculty

ProfessorDivision of Medical SciencesUniversity of Northern British Columbia

Robert Olson

Professor

Division of Medical Sciences

University of Northern British Columbia

Prince George, British Columbia, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
97 publications in the last five years, latest in 2026.
Senior (last) author on 30 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2019.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

666

Publications

59,886

Citations

140

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Northern British Columbia profile.

Cancer Clinical Trials Rural and Northern Health Health Services Research

Latest papers

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.
The Lancet. Oncology · 2026
Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.
International journal of radiation oncology, biology, physics · 2026 · senior author
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
International journal of radiation oncology, biology, physics · 2026

All 666 publications

Latest funding

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3
CIHR · 2019 · Nominated PI
$699,380
Survivorship: A Key to Unlocking the Potential of Shared Care
CIHR · 2011 · Co-investigator
$21,101

All 2 grants and awards

From the 150 most recent of 666 publications.

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P

The Lancet. Oncology202624 citationsOpen Access

DOI: 10.1016/s1470-2045(25)00658-8 PMID: 41643695

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Leclerc C, Baker S, Jiang W, Mou B, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Chng N, Matthews Q, Benny A, Tyldesley S, Olson R

International journal of radiation oncology, biology, physics20262 citationsSenior author

DOI: 10.1016/j.ijrobp.2026.01.012 PMID: 41580164

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

Kooyman A, Chang JS, Liu M, Jiang W, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, Olson R, Baker S

International journal of radiation oncology, biology, physics20262 citations

DOI: 10.1016/j.ijrobp.2025.03.079 PMID: 40216089

Nomogram for Risk-Adaptive Estimation of the Locoregional Control Benefit Following Postoperative Radiation Therapy for Pathologic N0 Oral Cavity Cancer: A Retrospective Analysis.

Gau M, Su J, Huang SH, Alfaraj FA, Olson R, Marta GN, Kowalski LP, Kohler HF, de Matos LL, Moraes FY, Xu W, Sanz-Garcia E, Hahn E, Kim JJ, McPartlin A, O'Sullivan B, Tsai CJ, Waldron J, Prisman E, Irish JC, Yao CMKL, de Almeida JR, Goldstein DP, Hope A, Hosni A

International journal of radiation oncology, biology, physics20261 citationsOpen Access

DOI: 10.1016/j.ijrobp.2025.09.011 PMID: 40972905

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Baker S, Leclerc C, Atmanspacher-Wirth H, Zhao Y, Schellenberg D, Clark H, Mou B, Liu M, Hsu F, Berrang T, Atrchian S, Bergman A, Chng N, Matthews Q, Chang JS, Tyldesley S, Olson R

International journal of radiation oncology, biology, physics2026Senior author

DOI: 10.1016/j.ijrobp.2025.01.031 PMID: 39923903

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Powis M, Barbera L, Cheung M, Conrod R, DeVera M, Edwards A, Esmail S, McTaggart-Cowan H, Olson R, Peacock S, Sayani A, Singh S, Ali A, Salmini J, Hack S, Krzyzanowska MK

Journal of telemedicine and telecare2026

DOI: 10.1177/1357633x261469083 PMID: 42573135

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)

Gouveia AG, Tao J, Pond G, Dong K, Ye A, Rosa AA, Palhares DM, Villafuerte CJQ, Anselmo P, Moraes FY

Prostate2026Open Access

DOI: 10.1002/pros.70233

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Olson R, Liu M, Bergman A, Mou B, Abraham H, Leclerc C, Carolan H, Schellenberg D, Jiang W, Alexander A, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Gautam D, Chng N, Matthews Q, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S, Baker S

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2026First author

DOI: 10.1016/j.radonc.2026.111532 PMID: 42140754

Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.

Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F, Rowe LS, Severin D, Giuliani ME, Bezjak A, Lok BH, Raman S, Chung P, Zhao Y, Ho CK, Lock M, Louie AV, Lefresne S, Carolan H, Liu M, Yau V, Ye A, Olson RA, Mou B, Mohamed IG, Petrik DW, Dosani M, Pai H, Valev B, Gaede S, Warner A, Palma DA

International journal of radiation oncology, biology, physics202544 citations

DOI: 10.1016/j.ijrobp.2024.08.031 PMID: 39168356

Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer

Ryan S. Huang, David J. Chen, Ali Benour, Ryan Cortez, Andrew Mihalache, Carlton Johnny, Andrea Bezjak, Robert Olson, Srinivas Raman

JAMA Oncology202523 citationsOpen Access

DOI: 10.1001/jamaoncol.2025.3153 PMID: 40932728

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2019

Subject: Prospective PhD student: Cancer Clinical Trials Dear Professor Olson, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3" (2019), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Robert Olson

Research

Latest papers

Latest funding

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.

Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.

Nomogram for Risk-Adaptive Estimation of the Locoregional Control Benefit Following Postoperative Radiation Therapy for Pathologic N0 Oral Cavity Cancer: A Retrospective Analysis.

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Development of a consensus-derived comprehensive virtual care evaluation framework in oncology.

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)

Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.

Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.

Patient-Reported Outcomes as Prognostic Indicators for Overall Survival in Cancer

A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3

Survivorship: A Key to Unlocking the Potential of Shared Care

Frequent collaborators

Dr. Olson

Devin Schellenberg

Scott Tyldesley

David Palma

Stewart Gaede

Michael Mckenzie

Michael Lock

Anand Swaminath

George Rodrigues

Glenn Bauman

Winson Cheung

A. Howard

Alanah Bergman

Greg Zaric

Ava John-Baptiste

Benjamin Lok

Gregory Zaric

Alan Nichol

Meredith Giuliani

Marc Gaudet

Alison Allan

Andrea Bezjak

Nafisha Lalani

John Waldron

Jean-Marc Bourque

Peter Chung

Rebecca Wong

C. Tsai

Andrew McPartlin

Jolie Ringash

Brian O'Sullivan

David Nguyen

Carlo DeAngelis

André-Guy Martin

Matthew Cheung

Edward Chow

Anthony Fyles

Ezra Hahn

Ali Hosni